thrombolysis therapy

Phase 3Small molecule

UUniversity of Erlangen-Nürnberg Medical School

thrombolysis therapy is one of 64 small molecule programs targeting Stroke. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeRecruiting

Pulmonary EmbolismActive, not recruiting

StrokePhase 3

Recruiting

Pulmonary EmbolismPreclinical

Active, not recruiting

Competition

Competitive Landscape

147 competitors in Stroke

#DrugCompanyPhaseTrials

thrombolysis therapy

UUniversity of Erlangen-Nürnberg Medical School

Phase 3

2 2

Zometa

Pfizer

Preclinical

1 3

Savella

AbbVie

Preclinical

1 4

Proamatine

Repatha

Haldol

1 7

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Zantac 150

CChattem

Preclinical

1 9

Alka-Seltzer

AAbbott

Preclinical

1 10

Inderal

Mylan Pharmaceuticals Inc

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

N/ARecruiting

Pulmonary Embolism

NCT06833827

Q4 2037

Phase 3Recruiting

Stroke

NCT06878066

Clinical

Trials by Indication[1]

Stroke2 trials

Stroke Research Consortium in Northern Bavaria (STAMINA)

Completed·UUniversity of Erlangen-Nürnberg Medical School··NCT04357899·3,769 enrolled

The Efficacy and Safety of Intravenous Thrombolysis in Acute Ischemic Stroke Patients With Recent Ingestion of Factor Xa-inhibitors Trial (SIFT)

Recruiting·GGuri Hagberg·Phase 3·NCT06878066·300 enrolled

Pulmonary Embolism1 trial

'Thrombectomy in High-Risk Pulmonary Embolism - Device Versus Thrombolysis Netherlands': TORPEDO-NL

Recruiting·LLeiden University Medical Center·N/A·NCT06833827·111 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for thrombolysis therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — thrombolysis therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for thrombolysis therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Erlangen-Nürnberg Medical School company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Erlangen-Nürnberg Medical School

thrombolysis therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q4 2037

Trials by Indication[1]

Stroke2 trials

Pulmonary Embolism1 trial

References

Drug Info

Quick Facts

Related News